HMG-CoA Reductase Inhibitors Suppress the Development and Progression of Carotid Artery Intimal-medial Thickening in Hypercholesterolemic Type 2 Diabetic Patients

Abstract

We reported previously that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (RIs) suppressed in vitro oxidized-low density lipoprotein-induced macrophage growth. To elucidate whether HMG-CoA RIs have anti-atherogenic effects separate from their cholesterol-lowering effect, total plasma levels of cholesterol in patients with type 2 diabetes mellitus (type 2 DM) and hypercholesterolemia were reduced to normal by one-year treatment with HMG-CoA RIs and intimal-medial thickness (IMT) of the common carotid arteries (CCA) was measured. Patients with type 2 DM and hypercholesterolemia received either pravastatin (n = 15) or simvastatin (n = 15), while another group of type 2 DM patients with normocholesterolemia did not receive these agents. IMT of the CCA was measured using Powervision SSA-370A, probe 7.5 Mhz. The mean IMT and the rate of increase of IMT were relatively elevated in the order of the simvastatin-treatment group, pravastatin-treatment group, and control group. Our results suggested that HMG-CoA RIs might have anti-atherogenic effects in addition to their cholesterol-lowering effect. J Atheroscler Thromb, 2005; 12: 149-153.

Stent material surface and glucose activate mononuclear cells of control, type 1 and type 2 diabetes subjects

“…Among the different parameters analyzed, cholesterol and glucose values were the only ones showing a significant difference between C and T1 and T2 subjects. No clear explanation could be offered about the lower levels of cholesterol in T2 subjects as results have been reported in literature showing high cholesterol levels in T2 unless therapeutically controlled 18, 19. Although other authors have shown significantly high blood levels of CRP in diabetic patients,20 this study showed no significant difference from the control.…”

Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus

“…Statins effectively reduce cardiovascular end points in type 2 diabetes (3). Regarding surrogate markers of atherosclerosis in type 2 diabetes, statins improve endothelial dysfunction (4,5) and reduce markers of endothelial activation and inflammation (6 -8), progression of intima-media thickness (9), and augmentation index (10,11).…”

Effects of Statins on Progression of Carotid Atherosclerosis as Measured By Carotid Intimal—Medial Thickness: A Meta-Analysis of Randomized Controlled Trials

“…Thus, 11 studies were included in our meta-analysis. 8,10,18-25 Takahashi et al 21 had 2 groups with different statin therapy regimens compared to placebo group. For the purpose of this meta-analysis, these 2 groups were treated as separate studies.…”